Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Basilea Pharmaceutica AG
  6. News
  7. Summary
    BSLN   CH0011432447

BASILEA PHARMACEUTICA AG

(BSLN)
  Report
Delayed Swiss Exchange  -  11:30:17 2023-02-07 am EST
47.95 CHF   -1.44%
02/07Basilea to Get Milestone Payment from Pfizer After Antifungal Drug Sales Exceed Threshold
MT
02/07Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers second sales milestone payment to Basilea from Pfizer
GL
02/07Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers second sales milestone payment to Basilea from Pfizer
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Basilea to Submit New Drug Application for Bloodstream Infection Drug Ceftobiprole in 2022-end

10/24/2022 | 02:04am EST
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about BASILEA PHARMACEUTICA AG
02/07Basilea to Get Milestone Payment from Pfizer After Antifungal Drug Sales Exceed Thresho..
MT
02/07Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China ..
GL
02/07Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China ..
AQ
02/07Continued strong Cresemba(R) (isavuconazole) sales performance in Asia Pacific and Chin..
DJ
01/24Basilea Pharmaceutica : Updated January 24, 2023
PU
01/24Basilea Forecasts Return to Profit in FY22 Over Anti-infectives Focus
MT
01/24Basilea reports preliminary operating profit for 2022, significantly above guidance
GL
01/24Basilea reports preliminary operating profit for 2022, significantly above guidance
DJ
01/24Basilea Pharmaceutica Ltd Revises Earnings Guidance for the Year 2022
CI
01/11Basilea Pharmaceutica : Updated January 11, 2023
PU
More news
Analyst Recommendations on BASILEA PHARMACEUTICA AG
More recommendations
Financials
Sales 2022 120 M 130 M 130 M
Net income 2022 -15,1 M -16,4 M -16,4 M
Net Debt 2022 89,7 M 97,1 M 97,1 M
P/E ratio 2022 -34,5x
Yield 2022 -
Capitalization 572 M 620 M 620 M
EV / Sales 2022 5,53x
EV / Sales 2023 4,71x
Nbr of Employees 177
Free-Float 88,1%
Chart BASILEA PHARMACEUTICA AG
Duration : Period :
Basilea Pharmaceutica AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BASILEA PHARMACEUTICA AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 47,95 CHF
Average target price 73,82 CHF
Spread / Average Target 53,9%
EPS Revisions
Managers and Directors
David Veitch Chief Executive Officer
Adesh Kaul Head-Corporate Development
Domenico Scala Chairman
Laurenz Kellenberger Chief Scientific Officer
Marc Engelhardt Head-Clinical Research
Sector and Competitors
1st jan.Capi. (M$)
BASILEA PHARMACEUTICA AG4.69%620
MODERNA, INC.-5.21%65 414
LONZA GROUP AG22.89%44 540
IQVIA HOLDINGS INC.13.38%43 149
ALNYLAM PHARMACEUTICALS, INC.-5.68%27 576
SEAGEN INC.6.95%25 250